In Brief: Fresenius USA
This article was originally published in The Gray Sheet
Executive SummaryFresenius USA: Firm's shareholders will receive approximately 1.112 American Depositary Shares (ADS) of the combined National Medical Care and Fresenius AG business -- Fresenius Medical Care AG -- for each share of Fresenius USA under a plan announced May 8. The plan allows Fresenius USA shareholders to "participate" in the pending combination of Grace's NMC with Fresenius AG ("The Gray Sheet" Feb. 12, p. 8). "Each ADS will evidence one-third of an ordinary share of Fresenius Medical Care AG," Fresenius USA and Fresenius AG say, noting that the exchange ratio is based on "the current intent" that 70 mil. ordinary shares of Fresenius Medical Care AG will be outstanding. After the deal's closing, Fresenius AG, Grace, and Fresenius USA shareholders will hold 50.3%, 44.8%, and 4.9% of the combined business, respectively...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.